Table III.
Treatment and outcome for advanced-stage and relapsed or refractory extranodal NK/T-cell lymphoma.
| Author (year) | N (stage III/IV) | Treatment regimen (n) | Outcomes
|
|
|---|---|---|---|---|
| % CR | % 5y OS | |||
| Advanced-stage | ||||
| Kwong et al. (1997) [57] | 24 (4) | CT + RT, stage III/IV | 25 | (2-month median) |
| Yong et al. (2001) [43] | 37 (11) | Overall | NR | 43 (2y) |
| CHOP | 27 | NR | ||
| CHOP followed by CMT | 46 | NR | ||
| Kim et al. (2003) [44] | 59 (18) | CHOP or COPBLAM-V + salvage RT | 36 | 44 |
| Chim et al. (2004) [28] | 67 (11) | Overall | 64 | 37 (20y) |
| Up-front RT (7) | NR | 83 (20y) | ||
| Up-front anthracycline-based CT + RT(59) | NR | 32 (20y) | ||
| Li et al. (2004) [31] | 77 (21) | Overall | 43 | NR |
| RT (1) | 0 | 0 | ||
| CHOP-based regimen(10) | 60 | 30 | ||
| RT + CT (10) | 30 | 20 | ||
| Yong et al. (2006) [48] | 46 (19) | CHOP +RT | 65 | 65 |
| Lee et al. (2006) [45] | 26 (10) | IMEP (14) ± salvage RT (12), stage III/IV | 13 | 30 (3y) |
| Pagano et al. (2006) [58] | 26 (8) | CT (9), CT + RT (14), CT + surgery (2), surgery (1) | 23 | 18 |
| Aviles et al. (2007) [59] | 61 (61) | CMED +RT | 80 | 65 |
| Guo et al. (2008) [29] | 63 (6) | Overall stage I–IV | NR | 70 |
| Overall stage III/IV | NR | 50 | ||
| CHOP (6) or CHOP + RT (53) | 49 | NR | ||
| RT + CHOP (4) | 100 | NR | ||
| Li et al. (2008) [40] | 91 (20) | Overall stage I–IV | 79 | 65 |
| Overall stage III | NR | 36 | ||
| Overall stage IV | NR | 22 | ||
| RT (13) | 77 | NR | ||
| CT (14) | 30 | NR | ||
| CHOP or CHOP-bleomycin + RT (46) | 85 | NR | ||
| RT + CT (18) | 89 | NR | ||
| Relapsed or refractory disease | ||||
| Yong et al. (2003) [60] | 18 | L-asparaginase, vincristine, dexamethasone | 56 | 56 |
| Jaccard et al. (2008) [61] | 18 | L-asparaginase, methotrexate, and dexamethasone | 56 | 72 (8-month) |
| Yamaguchi et al. (2008) [62] | 6 | SMILE | 50 | NR |
Y, year; NR, not reported; CT, chemotherapy; RT, radiotherapy; CMT, combined modality therapy (chemoradiotherapy); CR, complete remission; OS, overall survival; SMILE, steroid dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CMED, cyclophosphamide, methotrexate, etoposide, and dexamethasone; COPBLAM-V, cyclophosphamide, doxorubicin, vincristine, prednisolone, bleomycin, procarbazine; IMEP, ifosfamide, methotrexate, etoposide, and prednisolone.